Two Sigma Advisers
MGX icon

Two Sigma Advisers’s Metagenomi Therapeutics MGX Stock Holding History

Two Sigma Advisers’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-201,300
Closed -$326K – 2233
2025
Q4 		$326K Buy
201,300
+150,900
+299% +$327K ﹤0.01% 1954
2025
Q3 		$119K Buy
+50,400
New +$102K ﹤0.01% 2212
2024
Q4 		– Sell
-30,300
Closed -$65.8K – 2575
2024
Q3 		$65.8K Buy
+30,300
New +$105K ﹤0.01% 2200

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers's MGX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 201,300 shares — an estimated $326K sold.

Two Sigma Advisers first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $326K in Q4 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 201,300 Metagenomi Therapeutics shares in Q1 2026, an estimated $326K.
  • Two Sigma Advisers first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Two Sigma Advisers's Metagenomi Therapeutics position peaked at $326K in Q4 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.